Repaglinide Tablets 0.5 Mg

Repaglinide Tablets 0.5 Mg

Repaglinide Tablets 0.5 Mg is an oral anti-diabetic medication used for the management of type 2 diabetes mellitus. It belongs to the class of meglitinides, which help control blood sugar levels by stimulating insulin release from the pancreas. This low-dose formulation is usually prescribed as a starting dose to reduce the risk of hypoglycemia and assess patient response. It is especially effective in controlling post-meal (postprandial) blood sugar spikes. Repaglinide is often used along with diet and exercise or in combination with other anti-diabetic medications for better glycemic control.

Mechanism of Action

Rapid Insulin Release

Repaglinide stimulates the pancreas to release insulin quickly in response to meals.

Post-Meal Glucose Control

This helps reduce blood sugar spikes after eating. For clinical insights, refer to American Diabetes Association (ADA) and for safety guidance, consult Mayo Clinic – Repaglinide Information.

Medical Uses

Repaglinide Tablets 0.5 Mg is used for:

• Type 2 diabetes mellitus
• Postprandial blood sugar control
• Combination therapy with other antidiabetic medications

It is commonly prescribed for flexible meal-time glucose management.

Dosage and Administration

Repaglinide Tablets 0.5 Mg is typically taken before meals (about 15–30 minutes prior), as directed by a healthcare provider. The dose may be adjusted based on blood sugar levels and response. It is important to skip the dose if a meal is skipped to avoid hypoglycemia.

Clinical Effectiveness

Clinical studies show that repaglinide effectively lowers post-meal blood sugar levels and improves overall glycemic control when used consistently.

Safety and Side Effects

Common Side Effects

• Hypoglycemia (low blood sugar)
• Headache
• Weight gain

Serious Risks

• Severe hypoglycemia
• Allergic reactions (rare)

Regular blood sugar monitoring is recommended. For more details, refer to Mayo Clinic – Repaglinide Information.

Contraindications and Precautions

Repaglinide Tablets 0.5 Mg should not be used in:

• Type 1 diabetes mellitus
• Diabetic ketoacidosis
• Severe liver disease

Use with caution in elderly patients or those at risk of hypoglycemia.

Drug Interactions

Repaglinide may interact with other medications that affect blood sugar levels, increasing the risk of hypoglycemia. Patients should inform their healthcare provider about all medicines they are taking. For further reading, refer to American Diabetes Association (ADA).

FAQs